SK287882B6 - Azaindoles derivatives, pharmaceutical composition containing thereof and their use - Google Patents
Azaindoles derivatives, pharmaceutical composition containing thereof and their use Download PDFInfo
- Publication number
- SK287882B6 SK287882B6 SK901-2002A SK9012002A SK287882B6 SK 287882 B6 SK287882 B6 SK 287882B6 SK 9012002 A SK9012002 A SK 9012002A SK 287882 B6 SK287882 B6 SK 287882B6
- Authority
- SK
- Slovakia
- Prior art keywords
- group
- pyrrolo
- alkyl
- methyl
- optionally substituted
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Ophthalmology & Optometry (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Transplantation (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Otolaryngology (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9930698.7A GB9930698D0 (en) | 1999-12-24 | 1999-12-24 | Chemical compounds |
US21581800P | 2000-07-05 | 2000-07-05 | |
PCT/GB2000/004993 WO2001047922A2 (fr) | 1999-12-24 | 2000-12-27 | Azaindoles |
Publications (2)
Publication Number | Publication Date |
---|---|
SK9012002A3 SK9012002A3 (en) | 2003-04-01 |
SK287882B6 true SK287882B6 (sk) | 2012-02-03 |
Family
ID=26316153
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SK901-2002A SK287882B6 (sk) | 1999-12-24 | 2000-12-27 | Azaindoles derivatives, pharmaceutical composition containing thereof and their use |
SK5027-2011A SK288019B6 (sk) | 1999-12-24 | 2000-12-27 | Azaindoles derivatives, their use and pharmaceutical composition containing thereof |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SK5027-2011A SK288019B6 (sk) | 1999-12-24 | 2000-12-27 | Azaindoles derivatives, their use and pharmaceutical composition containing thereof |
Country Status (27)
Country | Link |
---|---|
US (2) | US6770643B2 (fr) |
EP (2) | EP1990343B1 (fr) |
JP (1) | JP5436507B2 (fr) |
KR (2) | KR100910488B1 (fr) |
CN (2) | CN100379734C (fr) |
AP (2) | AP1917A (fr) |
AU (1) | AU777717B2 (fr) |
BG (2) | BG66066B1 (fr) |
BR (1) | BR0017038A (fr) |
CA (2) | CA2395593C (fr) |
CY (1) | CY1110951T1 (fr) |
CZ (2) | CZ301750B6 (fr) |
DZ (1) | DZ3377A1 (fr) |
EA (1) | EA005212B1 (fr) |
EE (1) | EE05180B1 (fr) |
HK (1) | HK1050191B (fr) |
HR (1) | HRP20020547B1 (fr) |
HU (1) | HUP0203895A3 (fr) |
IL (3) | IL150388A0 (fr) |
MA (1) | MA26857A1 (fr) |
MX (1) | MXPA02006338A (fr) |
NO (2) | NO323766B1 (fr) |
NZ (1) | NZ519121A (fr) |
OA (1) | OA12514A (fr) |
PL (1) | PL209572B1 (fr) |
SK (2) | SK287882B6 (fr) |
WO (1) | WO2001047922A2 (fr) |
Families Citing this family (137)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CZ301750B6 (cs) | 1999-12-24 | 2010-06-09 | Aventis Pharma Limited | Bicyklický pyrrolový derivát, jeho použití pri výrobe léciva, farmaceutická kompozice tento derivát obsahující a pro použití pri lécení |
EP1363705B9 (fr) * | 2001-02-02 | 2012-11-07 | Bristol-Myers Squibb Company | Composition et activite antivirale de derives de piperazine azaindoleoxoacetique substitues |
GB0108770D0 (en) | 2001-04-06 | 2001-05-30 | Eisai London Res Lab Ltd | Inhibitors |
GB0115109D0 (en) * | 2001-06-21 | 2001-08-15 | Aventis Pharma Ltd | Chemical compounds |
WO2003000690A1 (fr) * | 2001-06-25 | 2003-01-03 | Aventis Pharmaceuticals Inc. | Synthese de composes heterocycliques faisant appel a une technologie micro-onde |
EP2335700A1 (fr) * | 2001-07-25 | 2011-06-22 | Boehringer Ingelheim (Canada) Ltd. | Inhibiteurs de la polymerase du virus hepatitis C avec une structure heterobicylic |
US20030158195A1 (en) | 2001-12-21 | 2003-08-21 | Cywin Charles L. | 1,6 naphthyridines useful as inhibitors of SYK kinase |
US6884889B2 (en) * | 2002-03-25 | 2005-04-26 | Bristol-Myers Squibb Co. | Processes for the preparation of antiviral 7-azaindole derivatives |
JP2005534619A (ja) * | 2002-03-28 | 2005-11-17 | エーザイ株式会社 | C−junn−末端キナーゼ阻害剤としてのアザインドール |
KR20040111445A (ko) * | 2002-03-28 | 2004-12-31 | 에자이 가부시키가이샤 | 신경퇴행성 질환 치료용 c─Jun N─말단 키나아제억제제로서의 7─아자인돌 |
US20050124620A1 (en) * | 2002-04-09 | 2005-06-09 | Martyn Frederickson | Pharmaceutical compounds |
AU2003224257A1 (en) * | 2002-04-09 | 2003-10-27 | Astex Technology Limited | Heterocyclic compounds and their use as modulators of p38 map kinase |
TW200307542A (en) * | 2002-05-30 | 2003-12-16 | Astrazeneca Ab | Novel compounds |
SE0201635D0 (sv) | 2002-05-30 | 2002-05-30 | Astrazeneca Ab | Novel compounds |
SE0202241D0 (sv) | 2002-07-17 | 2002-07-17 | Astrazeneca Ab | Novel Compounds |
EP1388541A1 (fr) | 2002-08-09 | 2004-02-11 | Centre National De La Recherche Scientifique (Cnrs) | Pyrrolopyrazines utilisées comme inhibiteurs de kinases |
EP1545515A1 (fr) | 2002-08-12 | 2005-06-29 | Sugen, Inc. | 3-pyrrolyl-pyridopyrazoles et 3-pyrrolyl-indazoles utilises en tant que nouveaux inhibiteurs de la proteine kinase |
SE0202464D0 (sv) * | 2002-08-14 | 2002-08-14 | Astrazeneca Ab | Use of compounds |
WO2004063181A1 (fr) * | 2003-01-03 | 2004-07-29 | Genzyme Corporation | Derives d'uree et leur utilisation comme agents anti-inflammatoires |
US7223785B2 (en) | 2003-01-22 | 2007-05-29 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
US7098231B2 (en) * | 2003-01-22 | 2006-08-29 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
GB0305142D0 (en) | 2003-03-06 | 2003-04-09 | Eisai London Res Lab Ltd | Synthesis |
EP2295433A3 (fr) * | 2003-03-06 | 2011-07-06 | Eisai R&D Management Co., Ltd. | Inhibiteurs de JNK |
SE0300908D0 (sv) | 2003-03-31 | 2003-03-31 | Astrazeneca Ab | Azaindole derivatives, preparations thereof, uses thereof and compositions containing them |
SE0301372D0 (sv) * | 2003-05-09 | 2003-05-09 | Astrazeneca Ab | Novel compounds |
EP1628975A2 (fr) | 2003-05-16 | 2006-03-01 | Eisai Co., Ltd. | Inhibiteurs des jnk |
SE0301569D0 (sv) | 2003-05-27 | 2003-05-27 | Astrazeneca Ab | Novel compounds |
RU2356889C2 (ru) | 2003-07-17 | 2009-05-27 | Плекссикон, Инк. | Соединения, являющиеся активными по отношению к рецепторам, активируемым пролифератором пероксисом |
SE0302232D0 (sv) | 2003-08-18 | 2003-08-18 | Astrazeneca Ab | Novel Compounds |
SE0303180D0 (sv) * | 2003-11-26 | 2003-11-26 | Astrazeneca Ab | Novel compounds |
JP2007514759A (ja) * | 2003-12-19 | 2007-06-07 | タケダ サン ディエゴ インコーポレイテッド | キナーゼ阻害剤 |
DK1718608T3 (da) * | 2004-02-20 | 2013-10-14 | Boehringer Ingelheim Int | Virale polymeraseinhibitorer |
FR2868422B1 (fr) | 2004-03-31 | 2006-07-14 | Aventis Pharma Sa | Nouveaux derives pyrrolo(2,3-b) pyridine, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases |
US20050250829A1 (en) * | 2004-04-23 | 2005-11-10 | Takeda San Diego, Inc. | Kinase inhibitors |
WO2006023931A2 (fr) * | 2004-08-18 | 2006-03-02 | Takeda San Diego, Inc. | Inhibiteurs de kinase |
FR2876103B1 (fr) | 2004-10-01 | 2008-02-22 | Aventis Pharma Sa | Nouveaux derives bis-azaindoles, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases |
WO2006044687A2 (fr) | 2004-10-15 | 2006-04-27 | Takeda San Diego, Inc. | Inhibiteurs de kinase |
AR054416A1 (es) | 2004-12-22 | 2007-06-27 | Incyte Corp | Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas. |
CA2589779A1 (fr) | 2004-12-23 | 2006-06-29 | F. Hoffmann-La Roche Ag | Derives benzamides, leur fabrication et leur utilisation comme agents pharmaceutiques |
WO2006066914A2 (fr) * | 2004-12-23 | 2006-06-29 | F. Hoffmann-La Roche Ag | Derives carbamates heterocycliques, leur fabrication et leur utilisation comme agents pharmaceutiques |
GB0500604D0 (en) | 2005-01-13 | 2005-02-16 | Astrazeneca Ab | Novel process |
US20060183758A1 (en) * | 2005-02-17 | 2006-08-17 | Cb Research And Development, Inc. | Method for synthesis of AZA-annelated pyrroles, thiophenes, and furans |
US8921376B2 (en) | 2005-05-20 | 2014-12-30 | Vertex Pharmaceuticals Incorporated | Pyrrolopyridines useful as inhibitors of protein kinase |
EP1910358A2 (fr) * | 2005-07-14 | 2008-04-16 | Astellas Pharma Inc. | Heterocycles inhibiteurs de janus kinase-3 |
CN102127078A (zh) * | 2005-07-14 | 2011-07-20 | 安斯泰来制药株式会社 | Janus激酶3的杂环类抑制剂 |
GB0516156D0 (en) | 2005-08-05 | 2005-09-14 | Eisai London Res Lab Ltd | JNK inhibitors |
CA2618682C (fr) * | 2005-08-12 | 2011-06-21 | Boehringer Ingelheim International Gmbh | Inhibiteurs de polymerase virale |
EP1926735A1 (fr) | 2005-09-22 | 2008-06-04 | Incyte Corporation | Inhibiteurs tetracycliques de janus kinases |
US8119655B2 (en) | 2005-10-07 | 2012-02-21 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
JP2009531274A (ja) * | 2005-12-07 | 2009-09-03 | オーエスアイ・ファーマスーティカルズ・インコーポレーテッド | キナーゼ阻害性ピロロピリジン化合物 |
LT2474545T (lt) | 2005-12-13 | 2017-02-27 | Incyte Holdings Corporation | Heteroarilu pakeisti pirolo[2,3-b]piridinai ir pirolo[2,3-b]pirimidinai kaip janus kinazės inhibitoriai |
PT1962830E (pt) * | 2005-12-23 | 2013-05-29 | Glaxosmithkline Llc | Inibidores azaindólicos de cinases aurora |
US20070208053A1 (en) * | 2006-01-19 | 2007-09-06 | Arnold Lee D | Fused heterobicyclic kinase inhibitors |
CA2651732C (fr) * | 2006-05-18 | 2014-10-14 | Mannkind Corporation | Inhibiteurs de kinases intracellulaires |
JP2009538289A (ja) | 2006-05-26 | 2009-11-05 | アストラゼネカ・アクチエボラーグ | ビアリールまたはヘテロアリール置換インドール |
WO2008014249A2 (fr) * | 2006-07-24 | 2008-01-31 | Sanofi-Aventis | Préparation améliorée de composés d'azaindole |
GB0617161D0 (en) * | 2006-08-31 | 2006-10-11 | Vernalis R&D Ltd | Enzyme inhibitors |
CL2007002617A1 (es) * | 2006-09-11 | 2008-05-16 | Sanofi Aventis | Compuestos derivados de pirrolo[2,3-b]pirazin-6-ilo; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar inflamacion de las articulaciones, artritis reumatoide, tumores, linfoma de las celulas del manto. |
EP2223925A1 (fr) * | 2006-10-09 | 2010-09-01 | Takeda Pharmaceutical Company Limited | Inhibiteurs de kinase |
GEP20135728B (en) | 2006-10-09 | 2013-01-25 | Takeda Pharmaceuticals Co | Kinase inhibitors |
WO2008079965A1 (fr) | 2006-12-22 | 2008-07-03 | Incyte Corporation | Hétérocycles substitués servant d'inhibiteurs de janus kinases |
CL2008001709A1 (es) | 2007-06-13 | 2008-11-03 | Incyte Corp | Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras. |
CA2689663C (fr) | 2007-06-13 | 2016-08-09 | Incyte Corporation | Sels de l'inhibiteur (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile de la janus kinase |
BRPI0820544A2 (pt) * | 2007-11-16 | 2015-06-16 | Incyte Corp | 4-pirazolil-n-arilpirimidin-2-aminas e pirazolil-n-heteroarilpirimidin-2-aminas como inibidores de janus cinase |
EP2245033B1 (fr) * | 2008-02-25 | 2011-08-31 | F. Hoffmann-La Roche AG | Inhibiteurs de la pyrrolopyrazine kinase |
ATE517107T1 (de) * | 2008-02-25 | 2011-08-15 | Hoffmann La Roche | Pyrrolopyrazinkinaseinhibitoren |
CA2713710A1 (fr) | 2008-02-25 | 2009-09-03 | F. Hoffmann-La Roche Ag | Inhibiteurs de la pyrrolopyrazine kinase |
CA2713718A1 (fr) | 2008-02-25 | 2009-09-03 | F. Hoffmann-La Roche Ag | Inhibiteurs de kinase pyrrolopyrazine |
CN101952294B (zh) | 2008-02-25 | 2014-11-26 | 霍夫曼-拉罗奇有限公司 | 吡咯并吡嗪激酶抑制剂 |
CN101965188A (zh) * | 2008-03-10 | 2011-02-02 | 赛诺菲-安万特 | 眼相关疾病的治疗 |
RS55263B1 (sr) | 2008-03-11 | 2017-02-28 | Incyte Holdings Corp | Derivati azetidina i ciklobutana kao jak inhibitori |
JP2011518836A (ja) * | 2008-04-24 | 2011-06-30 | インサイト・コーポレイション | 大環状化合物およびそれらのキナーゼ阻害剤としての使用 |
CL2009001884A1 (es) * | 2008-10-02 | 2010-05-14 | Incyte Holdings Corp | Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco. |
WO2010046215A2 (fr) * | 2008-10-21 | 2010-04-29 | Syngenta Participations Ag | Dérivés de diazaindole et leur emploi en tant que fongicides |
WO2010085597A1 (fr) | 2009-01-23 | 2010-07-29 | Incyte Corporation | Composés macrocycliques et leur utilisation en tant qu'inhibiteurs des kinases |
US20110112101A1 (en) * | 2009-03-05 | 2011-05-12 | Sanofi-Aventis | Treatment for ocular-related disorders |
AR075869A1 (es) * | 2009-03-19 | 2011-05-04 | Sanofi Aventis | Sintesis de azaindoles |
DK2432472T3 (da) | 2009-05-22 | 2019-11-18 | Incyte Holdings Corp | 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octan- eller heptan-nitril som jak-inhibitorer |
BRPI1012159B1 (pt) | 2009-05-22 | 2022-01-25 | Incyte Holdings Corporation | Compostos derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo[2,3-d] pirimidinas e pirrol-3-il-pirrolo[2,3-d] pirimidinas como inibidores de janus cinase, composições farmacêuticas compreendendo os referidos compostos e usos dos mesmos |
MX2012000711A (es) * | 2009-07-15 | 2012-03-16 | Abbott Lab | Inhibidores de pirrolopirazina de cinasas. |
CA2771939A1 (fr) | 2009-08-26 | 2011-03-03 | Nycomed Gmbh | Methylpyrrolopyrimidine-carboxamides |
TW201113285A (en) * | 2009-09-01 | 2011-04-16 | Incyte Corp | Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
CA2777114C (fr) | 2009-10-09 | 2018-10-23 | Incyte Corporation | Derives hydroxy, ceto et glucuronides de 3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3- cyclopentylpropanenitrile |
EP2338890A1 (fr) | 2009-12-22 | 2011-06-29 | Bayer CropScience AG | Dérivés de 4,7-diazaindole et leur utilisation en tant que fongicides |
AU2011217961B2 (en) * | 2010-02-18 | 2016-05-05 | Incyte Holdings Corporation | Cyclobutane and methylcyclobutane derivatives as Janus kinase inhibitors |
WO2011109932A1 (fr) * | 2010-03-09 | 2011-09-15 | F.Hoffmann-La Roche Ag | Nouveau procédé pour la fabrication de 7-azaindoles 5-halogénés |
KR20220015492A (ko) * | 2010-03-10 | 2022-02-08 | 인사이트 홀딩스 코포레이션 | Jak1 저해제로서의 피페리딘4일 아제티딘 유도체 |
US8481541B2 (en) | 2010-03-22 | 2013-07-09 | Hoffmann-La Roche Inc. | Pyrrolopyrazine kinase inhibitors |
US8518945B2 (en) | 2010-03-22 | 2013-08-27 | Hoffmann-La Roche Inc. | Pyrrolopyrazine kinase inhibitors |
JP2013526558A (ja) | 2010-05-20 | 2013-06-24 | エフ.ホフマン−ラ ロシュ アーゲー | Syk及びjak阻害剤としてのピロロピラジン誘導体 |
PL2574168T3 (pl) | 2010-05-21 | 2016-10-31 | Preparaty inhibitora kinazy janusowej do stosowania miejscowego | |
CA2818542A1 (fr) | 2010-11-19 | 2012-05-24 | Incyte Corporation | Derives pyrrolopyridine et pyrrolopyrimidine a substitution cyclobutyle utilises comme inhibiteurs des jak |
ES2536415T3 (es) | 2010-11-19 | 2015-05-25 | Incyte Corporation | Pirrolopiridinas y pirrolopirimidinas sustituidas heterocíclicas como inhibidores de JAK |
ES2547916T3 (es) | 2011-02-18 | 2015-10-09 | Novartis Pharma Ag | Terapia de combinación de inhibidores de mTOR/JAK |
US9145391B2 (en) | 2011-05-10 | 2015-09-29 | Merck Sharp & Dohme Corp. | Bipyridylaminopyridines as Syk inhibitors |
AU2012253885A1 (en) | 2011-05-10 | 2013-10-31 | Merck Sharp & Dohme Corp. | Aminopyrimidines as Syk inhibitors |
WO2012154520A1 (fr) | 2011-05-10 | 2012-11-15 | Merck Sharp & Dohme Corp. | Pyridylaminopyridines en tant qu'inhibiteurs de syk |
EP2721028B1 (fr) | 2011-06-20 | 2015-11-04 | Incyte Corporation | Dérivés d'azétidinyl-phényl-, de pyridyl- ou de pyrazinyl-carboxamide en tant qu'inhibiteurs des jak |
US9358229B2 (en) | 2011-08-10 | 2016-06-07 | Novartis Pharma Ag | JAK PI3K/mTOR combination therapy |
TW201313721A (zh) | 2011-08-18 | 2013-04-01 | Incyte Corp | 作為jak抑制劑之環己基氮雜環丁烷衍生物 |
DE102011111400A1 (de) * | 2011-08-23 | 2013-02-28 | Merck Patent Gmbh | Bicyclische heteroaromatische Verbindungen |
UA111854C2 (uk) | 2011-09-07 | 2016-06-24 | Інсайт Холдінгс Корпорейшн | Способи і проміжні сполуки для отримання інгібіторів jak |
WO2013052394A1 (fr) | 2011-10-05 | 2013-04-11 | Merck Sharp & Dohme Corp. | Inhibiteurs de tyrosine kinase de la rate (syk) contenant un 2-pyridyl carboxamide |
WO2013052393A1 (fr) | 2011-10-05 | 2013-04-11 | Merck Sharp & Dohme Corp. | Inhibiteurs de tyrosine kinase de la rate (syk) contenant un 3-pyridyl carboxamide |
WO2013052391A1 (fr) | 2011-10-05 | 2013-04-11 | Merck Sharp & Dohme Corp. | Inhibiteurs de tyrosine kinase de la rate (syk) contenant un phényl carboxamide |
CA2863717C (fr) * | 2012-02-21 | 2021-09-28 | Lars Burgdorf | Derives de furopyridine |
WO2013173720A1 (fr) | 2012-05-18 | 2013-11-21 | Incyte Corporation | Dérivés de pyrrolopyridine et de pyrrolopyrimidine substitués par un pipéridinylcyclobutyle à titre d'inhibiteurs jak |
WO2013192128A1 (fr) | 2012-06-20 | 2013-12-27 | Merck Sharp & Dohme Corp. | Analogues d'imidazolyle en tant qu'inhibiteurs de syk |
US9242984B2 (en) | 2012-06-20 | 2016-01-26 | Merck Sharp & Dohme Corp. | Pyrazolyl derivatives as Syk inhibitors |
WO2013192088A1 (fr) | 2012-06-22 | 2013-12-27 | Merck Sharp & Dohme Corp. | Inhibiteurs de tyrosine kinase splénique (syk) diazines et triazines substituées |
US9376418B2 (en) | 2012-06-22 | 2016-06-28 | Merck Sharp & Dohme Corp. | Substituted pyridine spleen tyrosine kinase (SYK) inhibitors |
ES2609126T3 (es) | 2012-07-26 | 2017-04-18 | Glaxo Group Limited | 2-(Azaindol-2-il)benzimidazoles como inhibidores de PAD4 |
US9353066B2 (en) | 2012-08-20 | 2016-05-31 | Merck Sharp & Dohme Corp. | Substituted phenyl-Spleen Tyrosine Kinase (Syk) inhibitors |
EP2900665B1 (fr) | 2012-09-28 | 2018-01-03 | Merck Sharp & Dohme Corp. | Dérivés triazolyle en tant qu'inhibiteurs de la syk |
PE20200175A1 (es) | 2012-11-15 | 2020-01-24 | Incyte Holdings Corp | Formas de dosificacion de ruxolitinib de liberacion sostenida |
UA120162C2 (uk) | 2013-03-06 | 2019-10-25 | Інсайт Холдінгс Корпорейшн | Способи і проміжні сполуки при отриманні інгібітора jak |
UY35419A (es) * | 2013-03-14 | 2014-10-31 | Abbvie Inc | Inhibidores de cdk9 quinasa de pirrolo (2,3- b) piridina |
EP2970264A1 (fr) | 2013-03-14 | 2016-01-20 | AbbVie Inc. | Inhibiteurs de pyrrolo[2,3-b]pyridine cdk9 kinase |
TWI634111B (zh) * | 2013-03-15 | 2018-09-01 | 普雷辛肯公司 | 雜環化合物及其用途 |
US20140303121A1 (en) | 2013-03-15 | 2014-10-09 | Plexxikon Inc. | Heterocyclic compounds and uses thereof |
CA3155500A1 (fr) | 2013-08-07 | 2015-02-12 | Incyte Corporation | Formes galeniques a liberation prolongee pour un inhibiteur jak1 |
US9498467B2 (en) | 2014-05-30 | 2016-11-22 | Incyte Corporation | Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1 |
EP3229798A4 (fr) | 2014-12-11 | 2018-05-30 | Beta Pharma, Inc. | Dérivés de 2-anilinopyrimidine substitués utilisés comme modulateurs de l'egfr |
US9938273B2 (en) | 2015-12-07 | 2018-04-10 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
WO2017151409A1 (fr) | 2016-02-29 | 2017-09-08 | University Of Florida Research Foundation, Incorporated | Méthodes de chimiothérapie |
WO2018191587A1 (fr) * | 2017-04-14 | 2018-10-18 | Syros Pharmaceuticals, Inc. | Inhibiteurs de kinases tam |
WO2018226846A1 (fr) | 2017-06-07 | 2018-12-13 | Plexxikon Inc. | Composés et procédés de modulation de kinase |
JP2020536917A (ja) | 2017-10-13 | 2020-12-17 | プレキシコン インコーポレーテッドPlexxikon Inc. | キナーゼを調節するための化合物の固体形態 |
US10596161B2 (en) | 2017-12-08 | 2020-03-24 | Incyte Corporation | Low dose combination therapy for treatment of myeloproliferative neoplasms |
CN112105608B (zh) | 2018-01-30 | 2023-07-14 | 因赛特公司 | 制备(1-(3-氟-2-(三氟甲基)异烟碱基)哌啶-4-酮)的方法 |
MX2020010322A (es) | 2018-03-30 | 2022-11-30 | Incyte Corp | Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de actividad de la cinasa janus (jak). |
KR20210106506A (ko) | 2018-12-21 | 2021-08-30 | 셀진 코포레이션 | Ripk2의 티에노피리딘 억제제 |
MX2021009863A (es) | 2019-03-21 | 2021-11-12 | Onxeo | Una molecula dbait en combinacion con inhibidor de quinasa para el tratamiento del cancer. |
KR20220098759A (ko) | 2019-11-08 | 2022-07-12 | 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) | 키나제 억제제에 대해 내성을 획득한 암의 치료 방법 |
EP4061367A1 (fr) | 2019-11-22 | 2022-09-28 | Incyte Corporation | Polythérapie comprenant un inhibiteur d'alk2 et un inhibiteur de jak2 |
WO2021148581A1 (fr) | 2020-01-22 | 2021-07-29 | Onxeo | Nouvelle molécule dbait et son utilisation |
US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
Family Cites Families (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB966264A (en) | 1961-08-31 | 1964-08-06 | Distillers Co Yeast Ltd | Production of alkyl pyridines |
GB1141949A (en) * | 1966-02-23 | 1969-02-05 | Sterling Drug Inc | 7-azaindole derivatives |
US3992392A (en) * | 1973-04-27 | 1976-11-16 | The Ohio State University Research Foundation | Synthesis of indoles from anilines and intermediates therein |
EP0405602A1 (fr) | 1989-06-30 | 1991-01-02 | Laboratorios Vinas S.A. | Dérivés zinciques de substances antiiflammatoires doués d'une activité thérapeutique améliorée |
US5202108A (en) * | 1990-10-12 | 1993-04-13 | Analytical Development Corporation | Process for producing ferrate employing beta-ferric oxide |
SE9100920D0 (sv) * | 1991-03-27 | 1991-03-27 | Astra Ab | New active compounds |
FR2687402B1 (fr) | 1992-02-14 | 1995-06-30 | Lipha | Nouveaux azaindoles, procedes de preparation et medicaments les contenant. |
JP3119758B2 (ja) | 1993-02-24 | 2000-12-25 | 日清製粉株式会社 | 7−アザインドール誘導体及びこれを有効成分とする抗潰瘍薬 |
US6756388B1 (en) | 1993-10-12 | 2004-06-29 | Pfizer Inc. | Benzothiophenes and related compounds as estrogen agonists |
US6075037A (en) * | 1994-06-09 | 2000-06-13 | Smithkline Beecham Corporation | Endothelin receptor antagonists |
US5521213A (en) | 1994-08-29 | 1996-05-28 | Merck Frosst Canada, Inc. | Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2 |
US5589482A (en) | 1994-12-14 | 1996-12-31 | Pfizer Inc. | Benzo-thiophene estrogen agonists to treat prostatic hyperplasia |
GB2298199A (en) | 1995-02-21 | 1996-08-28 | Merck Sharp & Dohme | Synthesis of azaindoles |
FR2732969B1 (fr) * | 1995-04-14 | 1997-05-16 | Adir | Nouveaux composes pyridiniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
AR004010A1 (es) | 1995-10-11 | 1998-09-30 | Glaxo Group Ltd | Compuestos heterociclicos |
EA199900021A1 (ru) | 1996-07-13 | 1999-08-26 | Глаксо, Груп Лимитед | Бициклические гетероароматические соединения в качестве ингибиторов протеинтирозинкиназы |
WO1998006703A1 (fr) | 1996-08-14 | 1998-02-19 | Warner-Lambert Company | Derives 2-phenyle benzimidazole en tant qu'antagonistes de mcp-1 |
US5783969A (en) | 1996-09-04 | 1998-07-21 | Motorola, Inc. | Method and system for preventing an amplifier overload condition in a hybrid matrix amplifier array |
DK0948495T3 (da) * | 1996-11-19 | 2004-06-01 | Amgen Inc | Aryl- og heteroarylsubstitueret, kondenseret pyrrol som antiinflammatoriske midler |
GB9708235D0 (en) * | 1997-04-23 | 1997-06-11 | Ciba Geigy Ag | Organic compounds |
AU7132998A (en) * | 1997-04-24 | 1998-11-13 | Ortho-Mcneil Corporation, Inc. | Substituted pyrrolopyridines useful in the treatment of inflammatory diseases |
DE69830409T2 (de) * | 1997-08-05 | 2006-01-26 | Pfizer Products Inc., Groton | 4-aminopyrrole[3,2-d]pyrimidine als neuropeptid rezeptor antagonisten |
WO1999020624A1 (fr) * | 1997-10-20 | 1999-04-29 | F.Hoffmann-La Roche Ag | Inhibiteurs bicycliques d'une kinase |
AU3210799A (en) * | 1998-04-02 | 1999-10-25 | Merck & Co., Inc. | Antagonists of gonadotropin releasing hormone |
EP1067929A1 (fr) | 1998-04-02 | 2001-01-17 | Merck & Co., Inc. | Antagonistes de l'hormone liberant la gonadotropine (gnrh) |
US6025366A (en) | 1998-04-02 | 2000-02-15 | Merck & Co., Inc. | Antagonists of gonadotropin releasing hormone |
CA2326139A1 (fr) | 1998-04-02 | 1999-10-14 | Merck & Co., Inc. | Antagonistes de la gonadoliberine |
WO1999051595A1 (fr) | 1998-04-02 | 1999-10-14 | Merck & Co., Inc. | Antagonistes de l'hormone liberant la gonadotropine (gnrh) |
WO1999051232A1 (fr) | 1998-04-02 | 1999-10-14 | Merck & Co., Inc. | Antagonistes de l'hormone liberant la gonadotropine (gnrh) |
CN1308622A (zh) | 1998-05-12 | 2001-08-15 | 美国家用产品公司 | 用于治疗胰岛素抗性和高血糖的联苯基氧代-乙酸 |
EP1086950B1 (fr) | 1998-05-26 | 2010-09-29 | Chugai Seiyaku Kabushiki Kaisha | Derives d'indole heterocycliques et derives de mono ou de di-azaindole |
US6232320B1 (en) | 1998-06-04 | 2001-05-15 | Abbott Laboratories | Cell adhesion-inhibiting antiinflammatory compounds |
CZ439199A3 (cs) * | 1998-07-10 | 2000-07-12 | Pfizer Products Inc. | 4-Aminopyrrol(3^-d)pyrimidiny jako antagonisty receptoru neuropeptidu Y |
HUP0200355A3 (en) * | 1998-09-18 | 2004-07-28 | Abbott Gmbh & Co Kg | 4-aminopyrrolopyrimidines as kinase inhibitors, pharmaceutical compositions containing them and their use |
JP4771442B2 (ja) | 1998-12-31 | 2011-09-14 | アベンティス・ファーマスーティカルズ・インコーポレイテツド | 未保護β−アミノエステル化合物のα−置換 |
ATE256666T1 (de) | 1999-06-04 | 2004-01-15 | Elan Pharma Int Ltd | Zusammensetzungen und methoden zur verhinderung des zelltods |
US6207699B1 (en) | 1999-06-18 | 2001-03-27 | Richard Brian Rothman | Pharmaceutical combinations for treating obesity and food craving |
PE20010306A1 (es) | 1999-07-02 | 2001-03-29 | Agouron Pharma | Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa |
US6387900B1 (en) | 1999-08-12 | 2002-05-14 | Pharmacia & Upjohn S.P.A. | 3(5)-ureido-pyrazole derivatives process for their preparation and their use as antitumor agents |
DE19944051A1 (de) | 1999-09-14 | 2001-03-15 | Wilke Heinrich Hewi Gmbh | Verriegelungsvorrichtung |
DE19951360A1 (de) | 1999-10-26 | 2001-05-03 | Aventis Pharma Gmbh | Substituierte Indole |
CZ301750B6 (cs) | 1999-12-24 | 2010-06-09 | Aventis Pharma Limited | Bicyklický pyrrolový derivát, jeho použití pri výrobe léciva, farmaceutická kompozice tento derivát obsahující a pro použití pri lécení |
YU54202A (sh) | 2000-01-18 | 2006-01-16 | Agouron Pharmaceuticals Inc. | Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije |
MXPA02007957A (es) | 2000-02-17 | 2002-11-29 | Amgen Inc | Inhibidores de cinasas. |
US6264966B1 (en) | 2000-02-22 | 2001-07-24 | Concat, Ltd. | Compounds with chelation affinity and selectivity for first transition elements and their use in cosmetics and personal care products, inhibition of metalloenzymes, and inhibition of reperfusion injury |
DE10009000A1 (de) | 2000-02-25 | 2001-08-30 | Basf Ag | Verfahren zur Herstellung substituierter Indole |
CA2400923A1 (fr) | 2000-02-25 | 2001-08-30 | Merck & Co., Inc. | Inhibiteurs de tyrosine-kinase |
GB0007657D0 (en) | 2000-03-29 | 2000-05-17 | Celltech Therapeutics Ltd | Chemical compounds |
WO2001079198A1 (fr) | 2000-04-18 | 2001-10-25 | Agouron Pharmaceuticals, Inc. | Pyrazoles permettant d'inhiber des proteines kinases |
WO2001082930A1 (fr) * | 2000-05-03 | 2001-11-08 | Tularik Inc. | Agents microbiens a base de pyrazole |
WO2001096336A2 (fr) | 2000-06-14 | 2001-12-20 | Warner-Lambert Company | Heterocyles bicycliques fondus -6,5 |
US6407259B1 (en) | 2000-07-28 | 2002-06-18 | Pfizer Inc. | Process for the preparation of pyrazoles |
US6897231B2 (en) | 2000-07-31 | 2005-05-24 | Signal Pharmaceuticals, Inc. | Indazole derivatives as JNK inhibitors and compositions and methods related thereto |
MXPA03002294A (es) | 2000-09-15 | 2005-09-08 | Vertex Pharma | Compuestos de pirazol utiles como inhibidores de proteina cinasa. |
GB0115109D0 (en) | 2001-06-21 | 2001-08-15 | Aventis Pharma Ltd | Chemical compounds |
-
2000
- 2000-12-27 CZ CZ20022207A patent/CZ301750B6/cs not_active IP Right Cessation
- 2000-12-27 CA CA2395593A patent/CA2395593C/fr not_active Expired - Fee Related
- 2000-12-27 EE EEP200200343A patent/EE05180B1/xx not_active IP Right Cessation
- 2000-12-27 CN CNB008175950A patent/CN100379734C/zh not_active Expired - Fee Related
- 2000-12-27 EP EP08162392A patent/EP1990343B1/fr not_active Expired - Lifetime
- 2000-12-27 WO PCT/GB2000/004993 patent/WO2001047922A2/fr active Application Filing
- 2000-12-27 MX MXPA02006338A patent/MXPA02006338A/es active IP Right Grant
- 2000-12-27 PL PL355819A patent/PL209572B1/pl unknown
- 2000-12-27 SK SK901-2002A patent/SK287882B6/sk not_active IP Right Cessation
- 2000-12-27 EA EA200200707A patent/EA005212B1/ru not_active IP Right Cessation
- 2000-12-27 KR KR1020077009139A patent/KR100910488B1/ko not_active IP Right Cessation
- 2000-12-27 CN CNA2004100789697A patent/CN1615873A/zh active Pending
- 2000-12-27 CZ CZ20080557A patent/CZ301751B6/cs not_active IP Right Cessation
- 2000-12-27 AP AP2006003492A patent/AP1917A/xx active
- 2000-12-27 SK SK5027-2011A patent/SK288019B6/sk not_active IP Right Cessation
- 2000-12-27 AU AU22094/01A patent/AU777717B2/en not_active Ceased
- 2000-12-27 BR BR0017038-0A patent/BR0017038A/pt active Search and Examination
- 2000-12-27 KR KR1020027008150A patent/KR100755622B1/ko not_active IP Right Cessation
- 2000-12-27 DZ DZ003377A patent/DZ3377A1/fr active
- 2000-12-27 IL IL15038800A patent/IL150388A0/xx unknown
- 2000-12-27 CA CA2699568A patent/CA2699568C/fr not_active Expired - Fee Related
- 2000-12-27 EP EP00985695A patent/EP1263759B1/fr not_active Expired - Lifetime
- 2000-12-27 HU HU0203895A patent/HUP0203895A3/hu unknown
- 2000-12-27 NZ NZ519121A patent/NZ519121A/en not_active IP Right Cessation
- 2000-12-27 AP APAP/P/2002/002516A patent/AP1587A/en active
- 2000-12-27 OA OA1200200199A patent/OA12514A/en unknown
-
2002
- 2002-06-17 MA MA26692A patent/MA26857A1/fr unknown
- 2002-06-18 BG BG106836A patent/BG66066B1/bg unknown
- 2002-06-21 HR HR20020547A patent/HRP20020547B1/xx not_active IP Right Cessation
- 2002-06-21 NO NO20023032A patent/NO323766B1/no not_active IP Right Cessation
- 2002-06-24 US US10/178,667 patent/US6770643B2/en not_active Expired - Lifetime
- 2002-06-24 IL IL150388A patent/IL150388A/en not_active IP Right Cessation
-
2003
- 2003-03-19 HK HK03102024.3A patent/HK1050191B/zh not_active IP Right Cessation
-
2004
- 2004-04-20 US US10/827,978 patent/US7227020B2/en not_active Expired - Lifetime
-
2006
- 2006-12-27 NO NO20066017A patent/NO330747B1/no not_active IP Right Cessation
-
2008
- 2008-08-21 IL IL193615A patent/IL193615A0/en unknown
-
2010
- 2010-03-18 BG BG10110623A patent/BG66176B1/bg unknown
- 2010-11-25 CY CY20101101074T patent/CY1110951T1/el unknown
-
2011
- 2011-09-08 JP JP2011195789A patent/JP5436507B2/ja not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100755622B1 (ko) | 아자인돌 | |
KR100915289B1 (ko) | 아자인돌 | |
ES2382759T3 (es) | Azaindoles |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Patent lapsed due to non-payment of maintenance fees |
Effective date: 20141227 |